Work

SGLT2 inhibitors in sepsis and critical illness: a precision-medicine perspective on mechanisms, evidence, and future trial design

Year: 2026
Type: article
Abstract: Sodium-glucose cotransporter-2 (SGLT2) inhibitors have transformed chronic cardiorenal care, but their role in sepsis and critical illness remains uncertain. This Review evaluates whether the anti-inflammatory, endothelial-stabilizing, metabolic, mitochondrial, and renal effects of SGLT2 inhibition can be translated into clinically meaningful benefit across the sepsis continuum. The mechanistic rationale is strong because several proposed drug effects map closely to recognized sepsis pathways, including endothelial barrier failure, immunometabolic dysregulation, mitochondrial dysfunction, regulated cell death, septic cardiomyopathy, and sepsis-associated acute kidney injury. However, clinical evidence remains limited and heterogeneous. Observational prior-use studies suggest favorable associations but are vulnerable to confounding, while the first large randomized trial in acute critical illness, DEFENDER, found no overall clinical benefit of dapagliflozin in a broad ICU population. Exploratory analyses have nevertheless generated signals related to diuresis, fluid balance, and loop-diuretic usage, supporting a more targeted research strategy. Current evidence does not support routine initiation of SGLT2 inhibitors during acute sepsis or septic shock outside clinical trials, particularly during active shock, fasting, unstable renal perfusion, or metabolic stress. Future studies should avoid all-comer sepsis designs and instead focus on phenotype-enriched populations, safer timing windows such as stabilization or de-resuscitation, and post-ICU cardiorenal recovery. Mechanism-aligned endpoints, structured safety monitoring, biomarker-informed enrichment, and adaptive translational trial designs will be essential to determine whether SGLT2 inhibition can move from biologic plausibility to clinical utility in sepsis and critical illness.
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7225864677
FWCI:
Cites: 61
Cited by:
Related to: 10